HOME
LOGIN
THE MEDICAL LETTER
Subscribe
Current Issue
Previous Issues
Reference Tables
ABOUT US
The Medical Letter, Inc.
CONTINUING EDUCATION
Exams
DRUG INTERACTIONS
CONTACT US
The Medical Letter Mobile Home Page
CURRENT
ISSUE
1549
Coagulation factor Xa (recombinant), inactivated-zhzo (andexanet alfa; Andexxa – Portola) has received accelerated approval from the FDA for urgent reversal of the anticoagulant effect of the direct factor Xa inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto). Andexanet alfa is the second antidote for a direct oral anticoagulant to become available in the US, and the fi rst for factor Xa inhibitors. Idarucizumab (Praxbind) was approved in 2015 for reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran...  read more...
More from issue 1549
Coming Soon
Drugs for Inflammatory Bowel Disease
Baricitinib (Olumiant) for Rheumatoid Arthritis
Lofexidine (Lucemyra) for Management of Opioid Withdrawal
Two New Drugs for Glaucoma
Recommend to Your Library  

We're Essential.   Begin your free trial  
Previous Issues
© 2018 The Medical Letter, Inc.